Please Wait
Applying Filters...
menu
    • menu
    SPI Pharma has been solving formulation challenges using superior functional materials.

    Virtual Booth

    Contact Supplier

    Seqens is an integrated global leader in pharmaceutical solutions & specialty ingredients, & custom-made solutions to our customers.

    Virtual Booth

    Contact Supplier

    dmfs-not-supported-m-2025-05-19

    Virtual Booth

    An Enquiry

    Chirogate is a professional Prostaglandin manufacturer.

    Virtual Booth

    Contact Supplier

    Temad- We think of world-class quality.

    Virtual Booth

    Contact Supplier

    jdmfs-not-supported-m-2025-04-28

    Virtual Booth

    An Enquiry

    Menu

    Oxaliplatin

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    INTERMEDIATES

    FINISHED DOSAGE FORMULATIONS

    DRUG PRODUCT COMPOSITIONS

    RELATED EXCIPIENT COMPANIES

    EXCIPIENTS BY APPLICATIONS

    DIGITAL CONTENT

    GLOBAL SALES INFORMATION

    MARKET PLACE

    PATENTS & EXCLUSIVITIES

    REF. STANDARDS & IMPURITIES

    PharmaCompass
    $ API Ref.Price (USD/KG) : 35,910Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Bold Therapeutics Presents Poster on BOLD-100 at AACR 2025
    Bold Therapeutics Presents Poster on BOLD-100 at AACR 2025

    30 Apr 2025

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/bold-therapeutics-presents-late-breaking-poster-on-bold-100s-unique-ability-to-mitigate-oxaliplatin-induced-peripheral-neuropathy-oipn-at-aacr-annual-meeting-2025-302442129.html

    PR NEWSWIRE
    30 Apr 2025
    Share Share
    Bold Therapeutics's BOLD-100 May Prevent Oxaliplatin Nerve Damage
    Bold Therapeutics's BOLD-100 May Prevent Oxaliplatin Nerve Damage

    28 Apr 2025

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/bold-therapeutics-announces-presentation-of-late-breaking-data-on-bold-100s-unique-ability-to-mitigate-oxaliplatin-induced-peripheral-neuropathy-oipn-302439701.html

    PR NEWSWIRE
    28 Apr 2025
    Share Share
    Pfizer angles Braftovi combo for full FDA approval
    Pfizer angles Braftovi combo for full FDA approval

    04 Feb 2025

    // PRESS RELEASE

    https://www.pfizer.com/news/press-release/press-release-detail/pfizers-braftovir-combination-regimen-significantly

    PRESS RELEASE
    04 Feb 2025
    Share Share
    Oxaliplatin Europe Offers EU GMP Approved Cancer Drug Mfg
    Oxaliplatin Europe Offers EU GMP Approved Cancer Drug Mfg

    27 Jul 2024

    // PRESS RELEASE

    https://www.naprodgroup.com/propofol_europe.php

    PRESS RELEASE
    27 Jul 2024
    Share Share
    Roche's Columvi Extends Large B-Cell Lymphoma Survival
    Roche's Columvi Extends Large B-Cell Lymphoma Survival

    15 Jun 2024

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2024/06/15/2899263/0/en/Roche-s-Phase-III-STARGLO-study-demonstrates-Columvi-significantly-extends-survival-in-people-with-relapsed-or-refractory-diffuse-large-B-cell-lymphoma.html

    GLOBENEWSWIRE
    15 Jun 2024
    Share Share
    Merrimack Reports Ipsen Announcement of Approval By The US FDA of Onivyde® (Irinotecan Liposome Injection) Plus 5 Fluorouracil/Leucovorin and Oxaliplatin (NALIRIFOX) as a First-Line Treatment for Metastatic Pancreatic Ductal Adenocarcinoma (mPDAC)
    Merrimack Reports Ipsen Announcement of Approval By The US FDA of Onivyde® (Irinotecan Liposome Injection) Plus 5 Fluorouracil/Leucovorin and Oxaliplatin (NALIRIFOX) as a First-Line Treatment for Metastatic Pancreatic Ductal Adenocarcinoma (mPDAC)

    14 Feb 2024

    // PRESS RELEASE

    https://investors.merrimack.com/news-releases/news-release-details/merrimack-reports-ipsen-announcement-approval-us-fda-onivyder

    PRESS RELEASE
    14 Feb 2024
    Share Share